

#### عنوان مقاله:

Point Mutations in RET Proto-Oncogene Exon 1º in Patients with Medullary Thyroid Carcinoma

**محل انتشار:** مجله دانشگاه علوم پزشکی کرمان, دوره 22, شماره 3 (سال: 1394)

تعداد صفحات اصل مقاله: 12

## نویسندگان:

Marjan Zarif-Yeganeh - Ph.D. Student, Cellular and Molecular Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Sara Sheikholeslami - Master of Biochemistry, Cellular and Molecular Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Golnoush Dehbashi-Behbahani - Master of Biochemistry, Cellular and Molecular Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Samaneh Farashi - Master of Human Genetics, Cellular and Molecular Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Laleh Hoghooghi-Rad - Master of Human Genetics, Cellular and Molecular Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Fereidoun Azizi - Professor, Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Mehdi Hedayati - Associate Professor, Cellular and Molecular Research Center, Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

### خلاصه مقاله:

Background & Aims: Thyroid cancer is the most common endocrine malignancy. Medullary thyroid carcinoma (MTC) is an aggressive malignant tumor arising from parafollicular cells of the thyroid. MTC occurs in hereditary (Y&%, hMTC) or sporadic (Y&%, sMTC) forms. The hMTC form has an autosomal dominant inheritance. RET proto-oncogene mutations, especially the Io, II, and IF exones, are associated with MTC. The aim of this study was to determine the type and frequency of RET proto-oncogene exon Io in patients with MTC. Methods: The study participants included MFY individuals, including YoY patients and IFo of their first degree relatives. Genomic DNA was extracted from peripheral leukocytes using salting out/Proteinase K method. All individuals were tested for RET mutations in exon Io using polymerase chain reaction (PCR)- DNA sequencing method. Results: A total of IF germline missense RET mutations were identified in cysteine codons FII, FIA, and FYo in II patients(Io mutation in males, F in females), and  $\Psi$  of their first-degree relatives (frequency:  $\Psi$ .F%) which were as follows: four CFIIY (three FMTC, one relative), one CFIAR (FMTC), one CFIAS (sMTC), one CFYoG (sMTC), four CFYoR (one FMTC, three sMTC), and three CFYoF (one FMTC, two relatives). The most predominant mutations in exon Io in our FMTC and sMTC patients were CFIIY and CFYoR, respectively. We did not find any mutations in cysteine codon Fo. Conclusion: In the present study, F different types of missense mutations were identified in exon 10 of RET in the nonsyndromic form of MTC. Based on the results of this study, mutation detection using DNA sequencing in exons 10, 11, and 19 of RET in patients with MTC and their relatives .is recommended

**کلمات کلیدی:** medullary thyroid cancer, RET proto-oncogene, Exon ۱۰, Germline mutation, Iranian population

# لینک ثابت مقاله در پایگاه سیویلیکا:

https://civilica.com/doc/1583334

